[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Amato R: Thalidomide for recurrent renal-cell cancer in a 40-year-old man. Oncology (Williston Park); 2000 Dec;14(12 Suppl 13):33-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
  • Anderson Cancer Center to determine the feasibility of using thalidomide in a population of renal-cell carcinoma patients who had progressive disease despite chemotherapy and immunotherapy.
  • Metastatic renal-cell carcinoma patients with adequate oral function were entered onto a study after signing an internal review board-approved informed consent.
  • There were no exclusion criteria for prior therapy.
  • Nineteen previously treated patients and one untreated patient with progressive renal-cell carcinoma received oral thalidomide as a single agent.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adult. Drug Therapy, Combination. Fluorouracil / therapeutic use. Humans. Interleukin-2 / therapeutic use. Male. Neoplasm Metastasis. Pilot Projects. Recurrence

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11204672.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Interleukin-2; 4Z8R6ORS6L / Thalidomide; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Izumi K, Kanno H, Umemoto S, Hasumi H, Osada Y, Otai J, Mikata K, Tsuchiya F, Nagashima Y: [A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration]. Hinyokika Kiyo; 2007 Sep;53(9):623-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration].
  • Right radical Computed tomography (CT) demonstrated an 8 cm mass in the right kidney. nephrectomy was done in March 1995, and the pathological examination revealed renal cell carcinoma (RCC), clear cell type, G2>G1.
  • About 3 years later, in March 1998, CT showed 1 cm mass in the left kidney.
  • Nine months later, in June 2001, the recurrence of the left kidney and the left adrenal gland was found and partial nephrectomy and adrenalectomy was performed.
  • Only 3 months later, recurrence of the left kidney and the left adrenal gland and the lymph node of renal hilus was found.
  • We gave up for surgical resection and chemotherapy of MVP (Methotrexate, Vinblastine, Pepleomycin) was performed.
  • Despite the therapy, disease progressed.
  • 10 months after the last recurrence, in July 2002, patient became disoriented and hypercalcemia and the MVP therapy was stopped.
  • MPA might be considered as a drug for advanced renal cell carcinoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Renal Cell / drug therapy. Medroxyprogesterone Acetate / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Etoposide / therapeutic use. Humans. Interferon-alpha / therapeutic use. Interferon-gamma / therapeutic use. Male. Middle Aged. Mitoxantrone / therapeutic use. Neoplasm Metastasis. Neoplasm Recurrence, Local. Nephrectomy. Thiotepa / therapeutic use

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933137.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Interferon-alpha; 6PLQ3CP4P3 / Etoposide; 82115-62-6 / Interferon-gamma; 905Z5W3GKH / Thiotepa; BZ114NVM5P / Mitoxantrone; C2QI4IOI2G / Medroxyprogesterone Acetate; MVT protocol
  •  go-up   go-down


3. Sawada N, Fukasawa M, Araki I, Kira S, Manabu K, Takeda M: Multifocal metastases of recurrent renal cell carcinoma successfully treated with a combination of low dose interleukin-2, alpha-interferon and radiotherapy. Int J Urol; 2005 Nov;12(11):994-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal metastases of recurrent renal cell carcinoma successfully treated with a combination of low dose interleukin-2, alpha-interferon and radiotherapy.
  • Left renal cell carcinoma stage II was diagnosed and radical left nephrectomy was performed.
  • The combination cytokine therapy was performed with 1.4 x 10(6) U of interleukin-2 (IL-2) and 3 x 10(6) U of IFN-alpha for 16 weeks, and the left sacroiliac joint metastasis was treated with radiation therapy of 4 Gy per day for 7 days.
  • Six months after the 16 weeks of immunotherapy, computed tomography and bone scintigraphy revealed that the metastases of the lung, liver and bone substantially disappeared and this complete response is still kept after 16 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Carcinoma, Renal Cell / therapy. Liver Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Dose-Response Relationship, Drug. Humans. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Kidney Neoplasms / pathology. Male. Middle Aged. Nephrectomy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351657.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Interleukin-2
  •  go-up   go-down


Advertisement
4. Miller AA, Pang H, Hodgson L, Ramnath N, Otterson GA, Kelley MJ, Kratzke RA, Vokes EE, Cancer and Leukemia Group B (CALGB): A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol; 2010 Mar;5(3):380-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).
  • INTRODUCTION: SRC is an oncogene with an essential role in the invasiveness and metastasis of solid tumors including small cell lung cancer.
  • The primary objective of this study was to determine the efficacy of second-line dasatinib in patients with chemosensitive (relapse or progression > or =90 days after completing first-line therapy) small cell lung cancer.
  • METHODS: Patients with measurable disease; performance status 0 to 1; no more than one prior platinum-based chemotherapy regimen; and adequate hematologic, hepatic, and renal function were eligible.
  • RESULTS: Between April 2007 and December 2008, 45 patients were enrolled, but one patient never received any protocol therapy and one patient was ineligible: male/female, 17/26; white/black/unknown, 40/2/1; median age, 64 years (range, 35-84 years); and performance status 0/1, 12/31.
  • With a median follow-up time of 7.1 months, median estimated overall survival and PFS times for the 43 eligible and treated patients were 17.0 and 5.9 weeks, respectively.
  • Common reasons for removal of patients from protocol treatment were progressive disease (65%) and adverse events (26%).

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Biol Chem. 1986 Oct 15;261(29):13754-9 [3093483.001]
  • [Cites] Mol Cell Biol. 1987 Dec;7(12):4178-84 [2830484.001]
  • [Cites] Am Rev Respir Dis. 1990 Dec;142(6 Pt 2):S54-6 [2174663.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2416-9 [1707753.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2291-6 [1722571.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):372-7 [1375484.001]
  • [Cites] Br J Cancer. 1993 Jan;67(1):37-46 [7678980.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):370-6 [8542594.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4255-63 [8797601.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2785-90 [8874340.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2090-6 [9164222.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):658-67 [10080612.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1811-6 [16087693.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):473-81 [16397263.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4539-44 [17008692.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1096-104 [17914079.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncogene. 2008 Mar 13;27(12):1737-48 [17906699.001]
  • [Cites] Int J Oncol. 2009 Mar;34(3):689-96 [19212674.001]
  • (PMID = 20087228.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77597; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / U10 CA086726; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA031946-28; United States / NCI NIH HHS / CA / U10 CA077597; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA114558; United States / NCI NIH HHS / CA / U10 CA045418; United States / NCI NIH HHS / CA / CA86726; United States / NCI NIH HHS / CA / CA031946-28; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / CA114558-02; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / U10 CA003927
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  • [Other-IDs] NLM/ NIHMS181118; NLM/ PMC2853764
  •  go-up   go-down


5. Dawson NA, Guo C, Zak R, Dorsey B, Smoot J, Wong J, Hussain A: A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res; 2004 Dec 1;10(23):7812-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
  • PURPOSE: The epidermal growth factor receptor (EGFR) is overexpressed in 75 to 90% of renal cell carcinomas and may play a role in tumor initiation and progression.
  • This trial was undertaken to assess the efficacy and toxicity of gefitinib in advanced renal cell carcinoma.
  • Patient characteristics were median age 61 (range, 35-78 years); 17 males, 4 females; median performance status 0 (range 0-2); median number of prior systemic therapies 1 (range, 0-3).
  • The median and mean number of cycles of therapy received was 3 and 4.7 (range, 1-14+).
  • CONCLUSIONS: Gefitinib is without significant conventional activity in renal cell carcinoma.
  • The relation of "stable disease" to treatment or to disease-related prognostic heterogeneity remains to be defined.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15585612.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA69854
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


6. Huisman C, Biesma B, Postmus PE, Giaccone G, Schramel FM, Smit EF: Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy. Br J Cancer; 2001 Nov 16;85(10):1456-61
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
  • The purpose of this study is to determine whether it is feasible to administer high-dose epirubicin (135 mg m(-2)) combined with a fixed dose of cisplatin every 2 weeks with G-CSF support in patients with metastatic non-small-cell lung cancer (NSCLC).
  • Subsequently, the efficacy of the recommended dose of this regimen was tested in a phase II study in patients with relapsed NSCLC.
  • 6 cases of febrile neutropenia were observed, with 2 treatment-related deaths.
  • Renal toxicity grade I and II occurred in 37% and 4% of patients, respectively.
  • 55% of these patients had received prior cisplatin-containing chemotherapy.
  • Accelerated cisplatin and high-dose epirubicin with G-CSF support is a feasible and promising regimen in relapsed NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Epirubicin / administration & dosage. Feasibility Studies. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematologic Diseases / etiology. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1992 Mar;65(3):405-8 [1313691.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):297-303 [1310105.001]
  • [Cites] Ann Oncol. 1992 Dec;3(10):864-6 [1337467.001]
  • [Cites] Semin Oncol. 1994 Feb;21(1 Suppl 1):48-53 [8153657.001]
  • [Cites] Eur J Cancer. 1994;30A(7):965-9 [7524579.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):297-303 [8996156.001]
  • [Cites] Lung Cancer. 1998 Oct;22(1):31-8 [9869105.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • [Cites] Br J Cancer. 2000 Jun;82(12):1914-9 [10864197.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3722-30 [11054445.001]
  • [Cites] Cancer Treat Rep. 1983 Jun;67(6):591-2 [6574820.001]
  • [Cites] Cancer Chemother Pharmacol. 1984;12(3):179-82 [6584236.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Apr;20(4):495-9 [6327315.001]
  • [Cites] Cancer Treat Rep. 1986 Jun;70(6):805-6 [2425963.001]
  • [Cites] Eur J Cancer. 1990;26(11-12):1140-1 [1963545.001]
  • [Cites] Eur J Cancer. 1991;27(10):1231-4 [1659841.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(3):212-4 [1321007.001]
  • (PMID = 11720428.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2363962
  •  go-up   go-down


7. Jermann M, Stahel RA, Salzberg M, Cerny T, Joerger M, Gillessen S, Morant R, Egli F, Rhyner K, Bauer JA, Pless M: A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol; 2006 Apr;57(4):533-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
  • Epidermal growth factor receptor (EGFR) expression has been associated with clinical outcome in some studies of renal-cell carcinoma (RCC).
  • This phase II trial recruited 28 patients with advanced, metastatic, or relapsed RCC.
  • At extended analysis (August 2004), median time to progression was 110 days (95% confidence interval [CI]: 55, 117); median overall survival was 303 days (95% CI 180, 444).
  • Skin rash and diarrhea were the most common drug-related adverse events (AEs) [54 and 39% of patients, respectively] and the most common drug-related grade 3/4 AEs (both 11%).
  • Gefitinib was generally well tolerated and no unexpected drug-related AEs were observed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, Epidermal Growth Factor / genetics. Recurrence. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16052341.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


8. Lin CM, Chen CH, Chang JW, Tsao TC: Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy. Am J Clin Oncol; 2009 Apr;32(2):169-73
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
  • BACKGROUND: We conducted a phase II study to evaluate the efficacy and toxicity of weekly docetaxel combined with epirubicin on D15 as second-line chemotherapy in Taiwanese patients with advanced non small cell lung cancer (NSCLC) who failed or relapsed after the frontline platinum-based chemotherapy.
  • Treatment was repeated every 4 weeks for a maximal total of 6 cycles.
  • The median time to disease progression for all patients was 2.8 months (95% CI 1.3-4.3%).
  • The median survival time for all patients was 7.7 months (95% CI 5.5-9.9%).
  • Hepatic and renal impairment was also only mild.
  • CONCLUSION: Combining weekly doses of docetaxel 30 mg/m with epirubicin 60 mg/m on D15 was not shown to improve both efficacy and tolerability for advanced NSCLC patients who have relapsed disease after frontline platinum-based chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Epirubicin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. Salvage Therapy. Survival Rate. Taxoids / administration & dosage. Treatment Failure

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307958.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


9. Wachters FM, van Putten JW, Boezen HM, Groen HJ: Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC. Lung Cancer; 2004 Aug;45(2):255-62
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC.
  • Aim of this study was to evaluate activity and toxicity of docetaxel and carboplatin as second-line treatment in advanced non-small-cell lung cancer (NSCLC) patients who failed or relapsed after previous chemotherapy.
  • Patients had to have unresectable stage IIIb or IV NSCLC, previous chemotherapy, a performance status < or = 2, a normal bone marrow reserve, and an adequate renal and liver function.
  • Treatment consisted of docetaxel 75 mg/m2 and carboplatin AUC 6 mg/ml min administered every 3 weeks for a maximum of 5 cycles.
  • Prior treatment consisted of gemcitabine alone (n = 2) or gemcitabine in combination with cisplatin (n = 26) or epirubicin (n = 29).
  • In conclusion, the combination of docetaxel and carboplatin is active as second-line treatment in platinum and non-platinum pre-treated patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / adverse effects. Carboplatin / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Logistic Models. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Risk Assessment. Survival Analysis. Taxoids / adverse effects. Taxoids / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15246198.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


10. Garst J: Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Expert Opin Drug Saf; 2007 Jan;6(1):53-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.
  • The topoisomerase I inhibitor, topotecan, is approved for the treatment of recurrent small-cell lung cancer (SCLC) and ovarian cancer (OC).
  • Patients with recurrent SCLC and OC typically experience multiple relapses and receive multiple rounds of chemotherapy.
  • In these settings, disease stabilisation is considered a treatment benefit, and quality-of-life effects and cumulative toxicities of treatments should be considered.
  • Many patients with recurrent cancer may be predisposed to treatment-related adverse events because of advanced age, renal impairment or extensive prior therapy.
  • Topotecan may provide physicians with a versatile therapeutic option for the treatment of patients with relapsed SCLC or OC.
  • [MeSH-major] Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Topotecan / adverse effects


11. Kosmas C, Tsavaris NB, Malamos NA, Vadiaka M, Koufos C: Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol; 2001 Jan 01;19(1):119-26
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
  • PURPOSE: The aim of the present phase II study was to evaluate the efficacy of the paclitaxel, ifosfamide, and cisplatin (PIC) combination in relapsed small-cell lung cancer (SCLC).
  • PATIENTS AND METHODS: Eligible patients were those with SCLC who had progressed or relapsed after therapy with carboplatin and etoposide (with or without chest radiotherapy).
  • Median time to progression and overall survival were 21 and 28 weeks, respectively.
  • Grade 3 and 4 toxicities included neutropenia in 30 patients (24 [73%] developed grade 4 neutropenia [ < 5 days]) and febrile neutropenia in six patients (18%); grade 3 or 4 thrombocytopenia was seen in nine patients (27%).
  • No grade 3 neuropathy was observed; grade 1 or 2 CNS toxicity was seen in five patients, there was no renal toxicity, grade 2 myalgias were seen in nine patients, grade 2 diarrhea was seen in one patient, and grade 3 nausea or vomiting was seen in seven patients.
  • There were no treatment-related deaths.
  • CONCLUSION: In the present phase II study, the PIC combination seemed highly active and tolerable in patients with relapsed SCLC when it was administered as second-line treatment.
  • Given the present experience, an evaluation of the PIC regimen as front-line treatment of SCLC is planned.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / drug therapy. Neoplasm Metastasis / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11134204.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Joerger M, Omlin A, Cerny T, Früh M: The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets; 2010 Jan;11(1):37-47
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action.
  • Pemetrexed is a newer antifolate drug that has been approved as first-line treatment for patients with advanced non-squamous, non-small cell lung cancer (NSCLC) in combination with cisplatin, and as single agent for relapsed or chemotherapy refractory NSCLC after platinum-containing chemotherapy, at a dose of 500 mg/m(2).
  • Pemetrexed undergoes rapid renal elimination as unchanged parent compound, with a terminal half-life of between two to five hours.
  • The results from the phase III upfront registration study, a retrospective observational data, and a recent maintenance study of pemetrexed in NSCLC suggest histological subtype to be the most important predictive marker for clinical outcome in patients receiving pemetrexed, Pemetrexed is active in patients with non-squamous cell NSCLC while no benefit is seen in patients with squamous-cell histology, possibly as a result of different expression of intratumoral TYMS.
  • These are important steps towards individualisation of anticancer treatment in patients with advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Glutamates / pharmacology. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19839929.001).
  • [ISSN] 1873-5592
  • [Journal-full-title] Current drug targets
  • [ISO-abbreviation] Curr Drug Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  • [Number-of-references] 94
  •  go-up   go-down


13. Hirschfeld S: Is participation in oncology clinical trials using gene therapy products safe. J Clin Oncol; 2004 Jul 15;22(14_suppl):6076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is participation in oncology clinical trials using gene therapy products safe.
  • This is particularly true for newer types of products such as gene therapy.
  • METHODS: A database maintained in MS Access containing all adverse events obtained from spontaneous reports and annual summaries of clinical trials using gene therapy products is being developed at the Center for Biologics Research and Evaluation at the the Food and Drug Administration.
  • Between 11000 and 12000 events obtained from spontaneous filings and annual reports submitted to the FDA have been entered of which about 7500 occurred in cancer patients.
  • The most common diagnoses were metastatic melanoma, glioblastome multiforme, squamous cell carcinoma of the lung, metastatic renal cell carcinoma, disseminated neuroblastoma, metastatic breast cancer and prostate cancer.
  • Detailed analysis of the patients, events, and products did not reveal other risk factors in addition to primary cancer diagnosis Conclusions: Participation in oncology gene therapy studies does not appear to carry additional risks beyond those expected of patients with relapsed or refractory disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014995.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Wiederkehr D, Casciano R, Stern L, Zheng J, Baladi J: Therapeutic care in metastatic renal cell carcinoma during the follow-up phase of the RECORD-1 phase III trial. J Clin Oncol; 2009 May 20;27(15_suppl):e17531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic care in metastatic renal cell carcinoma during the follow-up phase of the RECORD-1 phase III trial.
  • : e17531 Background: Following drug discontinuation for progression or adverse event in a clinical trial for relapsed or stage IV kidney cancer, supportive care including surgery, palliative radiotherapy, or bisphosphonates continue to be recommended by National Comprehensive Cancer Network (NCCN).
  • However, published data on active therapeutic agents given to patients following study drug discontinuation in recent clinical trials is limited.
  • METHODS: World Health Organization Anatomical Therapeutic Chemical codes or therapeutic names, captured from the follow-up phase in a phase III clinical trial (RECORD-1) of patients with metastatic renal cell carcinoma (mRCC) patients, were used to describe antineoplastic therapies following discontinuation of study drug.
  • Prior to trial, patients had progressed on at least one VEGFr-TKI therapy.
  • RESULTS: Of the 130 patients with follow-up after discontinuation of study drug, 78.5% received at least one of the following: corticosteroids, radiotherapy, protein kinase inhibitors, mTOR inhibitor, pyrimidine analogues, monoclonal antibodies, interferons, and investigational drugs.
  • Among patients who received an active agent, nearly three-quarters (73.5%) utilized targeted therapy (protein kinase inhibitors, mTOR inhibitor, monoclonal antibodies).
  • CONCLUSIONS: In a clinical trial setting with mRCC patients who have received several classes of systemic therapy, care delivered following study drug discontinuation often includes an active antineoplastic agent, despite the limited supportive evidence in this setting.
  • While the placebo control with supportive care in a double-blind phase is acceptable to evaluate the efficacy and safety of a therapy for regulatory approval purposes, decision makers must also consider how these data may inform comparisons with the usual alternatives available to and used by physicians and patients in the non-trial setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963810.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Manji M, Raja MA, Kerr I, Badawi I: Concurrent chemoradiation therapy (CCRT) with weekly Cisplatin in locally advanced cancer cervix (LACC): Single institution experience. J Clin Oncol; 2004 Jul 15;22(14_suppl):5107

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiation therapy (CCRT) with weekly Cisplatin in locally advanced cancer cervix (LACC): Single institution experience.
  • We review our experience with use of weekly cisplatin concurrent with radiation therapy (RT) during a three-year period.
  • All patients had external beam radiation therapy (EBRT) 4500 cGy + boost 540 cGy in 28 fractions followed by single application brachytherapy with cesium, delivering 3000 cGy to point A + parametrial boost.
  • Chemotherapy: cisplatin 40 mg/m<sup>2</sup> (30 mg/m<sup>2</sup> if para aortic nodes included in RT) weekly for 5 doses starting with RT.
  • Diagnosis by punch biopsy all patients with 32 squamous cell carcinoma, 1 poorly differentiated carcinoma.
  • All patients had normal baseline blood count and renal function.
  • Three interruptions during therapy, 14 short delays.
  • Chemotherapy 11 delays, 3 dose reductions.
  • No grade 3 or 4 hematologic/renal toxicity.
  • Ten relapsed -4 locally, 3 distant, 3 both.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015692.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Srkalovic G, Hussein M, Bolejack V, Hoering A, Zonder J, Barlogie B: A phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434). J Clin Oncol; 2009 May 20;27(15_suppl):e19517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As the frequency of these mutations increases with advancing disease and increasing drug resistance, inhibition of the RAF/MEK/ERK signaling pathway, as well the angiogenic VEGFR-2/PDGFR beta cascade by sorafenib may be a useful new approach for the treatment of MM.
  • METHODS: SWOG evaluated the effect of sorafenib as a single agent in relapsed/refractory MM patients.
  • In this phase II study we assessed response rate, overall (OS) and progression-free survival (PFS) as well as toxicities associated with this treatment.
  • This dose was based on the label for metastatic renal cell carcinoma.
  • Three patients experienced Grade 4 toxicity consisting of thrombocytopenia, anemia and renal failure.
  • As the frequency of RAS oncogene mutations increases resulting in resistance to traditional chemotherapeutic agents as well as possibly supporting cytokine resistance to immune modulators, sorafenib might have a supportive role in combination therapy with bortezomib, lenalidomide or everolimus in relapsed/refractory MM which is currently being evaluated in ongoing studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960944.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Battaglia M, Gernone A: Long-term use of sorafenib (SOR) in metastatic renal cell carcinoma (mRCC) previously treated with systemic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16123

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term use of sorafenib (SOR) in metastatic renal cell carcinoma (mRCC) previously treated with systemic therapy.
  • : e16123 Background: The recent development of new targeted agents for the treatment of advanced RCC has definitely changed the approach and the outcome of this disease.
  • Among them, SOR, has proved to be highly active in the treatment of mRCC.
  • The aim of this study was to assess the activity and the safety of SOR in pts with mRCC relapsed after prior systemic therapy.
  • METHODS: Between 2/2007 and 10/2008, 22 pts with mRCC relapsed after 1-2 prior lines of chemotherapy (gemcitabine, vinorelbine, 5-FU) have been treated with SOR orally administered at the dose of 400mg b.i.d. continuous dosing.
  • The primary endpoints were response rate (RR) evaluated by RECIST criteria and time to progression (TTP).
  • RESULTS: To date, 20 pts are evaluable for response: of them, 13 (59%) achieved a partial response (PR) after 3 mos. of therapy whose median duration was 13 mos. (range, 7-18), while 7 (31%) remained with stable disease (SD) with a median length of 14 mos. (range, 5-17).
  • Among those who progressed (2 pts), the median time to disease progression was 7 mos.
  • At a median length of time of 15 mos., 18 pts. are continuing the therapy with SOR and in all of them the benefit achieved remained unchanged.
  • Two pts discontinued the treatment because of the onset of side effects, while in 4 pts dose reductions were required.
  • However, notwithstanding the rather small sample size of pts., the overall clinical benefit rate (PR+SD) turned out particularly high (> 90%): chiefly, the evidence of a long lasting disease control both for patients achieving partial response and for those with stable disease makes SOR a very useful treatment for patients with mRCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963393.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Dancey JE, Curiel R, Purvis J: Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol; 2009 Dec;36 Suppl 3:S46-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temsirolimus, a novel analog of rapamycin, has shown promising preclinical and early clinical anti-tumor activity in various solid and hematologic tumor types, either alone or in combination with chemotherapy or other targeted agents.
  • Randomized phase III trials have already demonstrated significant clinical benefits of treatment with single-agent temsirolimus in advanced renal cell carcinoma and relapsed and/or refractory mantle cell lymphoma.
  • Other malignancies studied in the phase I and II trial settings include glioblastoma, breast cancer, endometrial cancer, non-Hodgkin lymphomas, and multiple myeloma.
  • [MeSH-major] Clinical Trials as Topic / methods. Neoplasms / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Disease Models, Animal. Drug Evaluation, Preclinical. Hematologic Neoplasms / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963100.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 91
  •  go-up   go-down


19. Shah RN, Ahmad T, Eisen TG: Treatment of recurrent or metastatic renal cell carcinoma. Expert Rev Anticancer Ther; 2004 Dec;4(6):1069-80
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent or metastatic renal cell carcinoma.
  • The management of recurrent renal cell carcinoma is challenging as it requires close collaboration between surgeons, radiation oncologists and medical oncologists.
  • To date, treatment options for metastatic disease have been of modest benefit.
  • The disease has therefore been a good model for novel drug development programs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606334.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 114
  •  go-up   go-down


20. Miller AA, Herndon JE 2nd, Gu L, Green MR, Cancer and Leukemia Group B: Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer; 2005 Jun;48(3):399-407
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
  • PURPOSE: This Phase II trial was designed to determine the response rate, survival, failure-free survival, and toxicity of second-line therapy with karenitecin in patients with relapsed or refractory non-small cell lung cancer (NSCLC).
  • METHODS: Eligibility criteria included: only one prior chemotherapy program, measurable disease, performance status 0-1, adequate hematologic, renal, and hepatic function.
  • Cases were stratified as relapsed or refractory.
  • RESULTS: Fifty-five patients were accrued and 52 were eligible of whom 28 had relapsed and 24 had refractory disease.
  • Overall patient characteristics were: median age 63 years (range, 45-79 years), 52% males, 63% performance status 1, 50% adenocarcinoma, 21% squamous, 15% large cell, and 12% undifferentiated NSCLC.
  • In both strata, one patient each (4%) had a partial response and 12 patients each (43% for relapsed, 50% for refractory) had stable disease.
  • Median survival was 10.4 months (95% CI, 8.5-17.0) for relapsed NSCLC and 6.0 months (95% CI, 3.7-9.7) for refractory NSCLC.
  • One-year survival was 36% (95% CI, 14-58%) and 21% (95% CI, 5-37%) for relapsed and refractory NSCLC, respectively.
  • CONCLUSION: Second-line treatment with karenitecin was tolerable with reversible bone marrow suppression as the major toxicity.
  • The partial response rates, median survival times, and 1-year survival rates in the relapsed and refractory subgroups are comparable to overall second-line outcomes for other agents considered active in this clinical setting.
  • [MeSH-major] Camptothecin / analogs & derivatives. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15893009.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA12046; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35421; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA86726
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 24R60NVC41 / cositecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Hashmi MH, Van Veldhuizen PJ: Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther; 2010 May;10(5):807-17
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
  • IMPORTANCE TO THE FIELD: In advanced renal cell cancer and malignant melanoma, the current FDA approved immune modulators, such as IL-2, are the only agents which provide a durable complete remission.
  • The identification of new immunotherapeutic agents with an improved response rate and toxicity profile would represent a significant advancement in the treatment of these malignancies.
  • In this review, we evaluate the development, pharmacologic properties, safety profile and current clinical efficacy of rIL-21.
  • TAKE HOME MESSAGE: rIL-21 has an acceptable safety profile and encouraging single agent activity in early phase renal cell carcinoma and melanoma clinical trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Immunotherapy / methods. Interleukins / therapeutic use. Kidney Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Melanoma / drug therapy
  • [MeSH-minor] Animals. Evidence-Based Medicine. Humans. Mice. Recombinant Proteins / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20384523.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukins; 0 / Recombinant Proteins; 0 / interleukin-21
  • [Number-of-references] 48
  •  go-up   go-down


22. Eralp Y, Saip P, Sakar B, Tas F, Aydiner A, Topuz E: Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix. Eur J Gynaecol Oncol; 2003;24(3-4):323-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.
  • The efficacy of a combination of cyclophosphamide and cisplatin in patients with metastatic and recurrent carcinoma of the cervix, was tested.
  • All patients received a median of four cycles of chemotherapy.
  • Overall response rate and progressive response in patients with relapse within the previous radiation field were 9.5% and 66.7%, respectively; while for patients who had recurrent disease outside any irradiated area both were 44.4%.
  • WHO grade 3 and 4 toxicity were anemia: 13 (43.3%), leucopenia: one (3.3%), thrombocytopenia: two (6.6%), renal: one, emesis: nine (30.0%) patients.
  • Univariate analysis revealed that progressive response to chemotherapy was the only prognostic factor for survival (7.1 vs 16.8 months, p = 0.003).
  • Further studies are required to determine a better therapeutic approach for patients with relapsed carcinoma of the cervix.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Biopsy, Needle. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Prospective Studies. Risk Assessment. Survival Rate. Treatment Outcome


23. Giantonio BJ, Hochster H, Blum R, Wiernik PH, Hudes GR, Kirkwood J, Trump D, Oken MM: Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs; 2001;19(1):89-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group.
  • PURPOSE: Phase II studies were conducted to evaluate the safety and efficacy of the interferon inducer Poly ICLC at low doses in advanced renal cancer and relapsed or refractory lymphoma.
  • PATIENTS AND METHODS: Twenty-nine patients with advanced renal carcinoma and eleven patients with lymphoma were treated with poly ICLC.
  • Six patients with renal carcinoma had stable disease as best response with one patient receiving 62 weeks of therapy.
  • CONCLUSION: Poly ICLC at this dose and schedule is well tolerated in both patient populations and is inactive in renal carcinoma.
  • [MeSH-major] Carboxymethylcellulose Sodium / administration & dosage. Carcinoma, Renal Cell / drug therapy. Interferon Inducers / administration & dosage. Kidney Neoplasms / drug therapy. Lymphoma / drug therapy. Poly I-C / administration & dosage. Polylysine / administration & dosage
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Multicenter Studies as Topic. Neoplasm Recurrence, Local. Neutropenia / chemically induced. Thrombocytopenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antimicrob Agents Chemother. 1977 Jan;11(1):80-3 [402107.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3005-10 [1591717.001]
  • [Cites] Cancer Res. 1979 May;39(5):1645-50 [371793.001]
  • [Cites] J Infect Dis. 1975 Oct;132(4):434-9 [810520.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5904-9 [2414002.001]
  • (PMID = 11291838.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 14958; United States / NCI NIH HHS / CA / CA 27525; United States / NCI NIH HHS / CA / CA 59307; etc
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Inducers; 24939-03-5 / Poly I-C; 25104-18-1 / Polylysine; 59789-29-6 / poly ICLC; K679OBS311 / Carboxymethylcellulose Sodium
  •  go-up   go-down


24. Galustian C, Dalgleish A: Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother; 2009 Jan;10(1):125-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide: a novel anticancer drug with multiple modalities.
  • Over the past 5 years, lenalidomide (Revlimid, Celgene Co., Summit, NJ, USA), a member of a class of drugs termed immunomodulatory drugs, has emerged as a significant weapon in the arsenal of cancer-therapeutics.
  • It is a lead therapeutic in multiple myeloma and del-5q myelodysplastic syndromes and has also been trialed for acute leukaemia and chronic lymphocytic leukaemia, relapsed or refractory Hodgkin's lymphoma, T-cell non-Hodgkin's lymphoma, prostate cancer, non-small cell lung cancer, malignant melanoma, renal cancer, advanced ovarian and peritoneal carcinoma.
  • The following review describes key clinical and mechanistic breakthroughs that have made lenalidomide a leading cancer therapeutic.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Thalidomide / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236186.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Number-of-references] 78
  •  go-up   go-down


25. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW: Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer; 2010 Jun 15;126(12):2762-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.
  • Arginine, a semi-essential amino acid in humans, is critical for the growth of human cancers, particularly those marked by de novo chemoresistance and a poor clinical outcome.
  • Several tumours are arginine auxotrophic, due to variable loss of ASS1, including hepatocellular carcinoma, malignant melanoma, malignant pleural mesothelioma, prostate and renal cancer.
  • Several phase I/II clinical trials of the arginine-lowering drug, pegylated arginine deiminase, have shown encouraging evidence of clinical benefit and low toxicity in patients with ASS1-negative tumours.
  • In part, ASS1 loss is due to epigenetic silencing of the ASS1 promoter in various human cancer cell lines and tumours, and it is this silencing that confers arginine auxotrophy.
  • In relapsed ovarian cancer, this is associated with platinum refractoriness.
  • In contrast, several platinum sensitive tumours, including primary ovarian, stomach and colorectal cancer, are characterised by ASS1 overexpression, which is regulated by proinflammatory cytokines.
  • This review examines the prospects for novel approaches in the prevention, diagnosis and treatment of malignant disease based on ASS1 pathophysiology and its rate-limiting product, arginine.
  • [MeSH-major] Arginine / metabolism. Argininosuccinate Synthase / metabolism. Neoplasms / enzymology. Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104527.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 12008; United Kingdom / Medical Research Council / / G0601891; United Kingdom / Cancer Research UK / / C12522/A8632
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 94ZLA3W45F / Arginine; EC 6.3.4.5 / Argininosuccinate Synthase
  • [Number-of-references] 86
  •  go-up   go-down


26. Baccala A Jr, Hedgepeth R, Kaouk J, Magi-Galluzzi C, Gilligan T, Fergany A: Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. Int J Urol; 2007 Dec;14(12):1095-7; discussion 1097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib.
  • Sunitinib is a highly potent, selective vascular endothelial growth factor-receptor types 1 to 3, platelet-derived growth factor (PDGF)-R-alpha, and PDGF-R-ss.
  • Preclinical data suggest that sunitinib (SU11248) has antitumor activity that may result from both inhibition of angiogenesis and direct antiproliferative effects on certain tumor cell types.
  • Sunitinib resulted in tumor shrinkage in 80% of patients who had failed treatment with Bevacizumab and 13% of patients demonstrated an objective Response Evaluation Criteria in solid Tumors (RECIST) in a study presented at the 2006 American Society of Clinical Oncology (ASCO) meeting.
  • We report the first published pathological evidence of sunitinib's effect on recurrent renal cell carcinoma.
  • This was seen in a patient with renal cell carcinoma who developed a renal fossa recurrence 2 years following radical nephrectomy.
  • Tumor shrinkage was evident in the nephrectomy bed after treatment with sunitinib.
  • [MeSH-major] Carcinoma, Renal Cell / drug therapy. Indoles / therapeutic use. Necrosis / chemically induced. Pyrroles / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036049.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


27. Armstrong DK, Spriggs D, Levin J, Poulin R, Lane S: Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist; 2005 Oct;10(9):686-94
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
  • The purpose was to conduct an integrated analysis of the cumulative hematologic toxicity of topotecan in patients with relapsed ovarian cancer and small cell lung cancer (SCLC).
  • Data were pooled from eight phase II and phase III clinical studies performed in patients with relapsed stage III/IV ovarian cancer or extensive SCLC treated with topotecan at a dose of 1.5 mg/m(2) per day on days 1-5 of a 21-day course.
  • Quantitative hematologic toxicities were assessed using the National Cancer Institute Common Toxicity Criteria.
  • A total of 4,124 courses of therapy was administered to the 879 patients in the pooled population.
  • The lowest nadirs for neutrophils and platelets generally occurred after the first course of therapy, followed by improvement or stabilization in subsequent courses.
  • During the first course, significant risk factors were identified: renal impairment and advanced age (grade 3/4 thrombocytopenia and grade 4 neutropenia) and prior radiotherapy; performance status score > or =2; SCLC; and exposure to both cisplatin (Platinol; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com) and carboplatin (Paraplatin; Bristol-Myers Squibb) (grade 3/4 thrombocytopenia only).
  • The most frequent interventions for hematologic toxicities were RBC transfusions, treatment delays, G-CSF support, and dose reductions.
  • Analysis of neutrophil and platelet nadirs and dosing for each course of therapy showed no apparent evidence of cumulative neutropenia or thrombocytopenia.
  • The risk of grade 3 or 4 anemia was higher during the first four courses of therapy and may need to be more aggressively managed with erythropoietin therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Marrow / drug effects. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Topotecan / adverse effects
  • [MeSH-minor] Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Erythropoietin / therapeutic use. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Hemoglobins / analysis. Humans. Male. Middle Aged. Neutropenia / chemically induced

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncologist. 2005 Oct;10(9):695-7 [16249348.001]
  • [CommentIn] Oncologist. 2006 May;11(5):529-31; author reply 531-2 [16720854.001]
  • [CommentIn] Oncologist. 2005 Oct;10(9):698-700 [16249349.001]
  • (PMID = 16249347.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hemoglobins; 11096-26-7 / Erythropoietin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan
  • [Number-of-references] 25
  •  go-up   go-down


28. Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, Spooner D, James ND: A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer; 2004 Aug 31;91(5):844-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
  • In all, 32 patients with locally advanced, relapsed, or metastatic disease received: dose level 1, G/C 1000/35; level 2, 1100/35; level 3, 1200/35; level 4, 1200/45 mg m(-2) (G and C given on days 1 and 8 every 3 wks).
  • Only seven cycles were deferred due to haematological toxicity; four for renal toxicity (chemotherapy instituted posthydration).
  • G plus C every 3 weeks is active and well tolerated in an outpatient setting, even in patients receiving prior platinum-based regimens and with poor renal reserve.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Maximum Tolerated Dose. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Kidney / drug effects. Kidney Function Tests. Lymphatic Metastasis / pathology. Male. Middle Aged. Outpatients. Treatment Outcome. Viscera / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] Curr Opin Urol. 2002 Sep;12(5):441-8 [12172434.001]
  • [Cites] Lancet Oncol. 2003 Aug;4(8):489-97 [12901963.001]
  • [Cites] J Urol. 1985 Mar;133(3):403-7 [4038749.001]
  • [Cites] J Clin Oncol. 1985 Nov;3(11):1463-70 [4056840.001]
  • [Cites] J Urol. 1989 Aug;142(2 Pt 1):289-92 [2746745.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3173-81 [10506615.001]
  • [Cites] Urology. 1989 Dec;34(6):353-6 [2595880.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1050-5 [2189954.001]
  • [Cites] J Urol. 1990 Sep;144(3):662-5 [2388322.001]
  • [Cites] Eur J Cancer. 1991;27(12):1690-4 [1782084.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1066-73 [1607913.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2564-9 [9215826.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2448-58 [2819654.001]
  • (PMID = 15292922.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2409873
  •  go-up   go-down


29. Thibault F, Izzedine H, Sultan V, Bart S, Billemont B, Rixe O, Bitker MO: [Regression of vena cava tumour thrombus in response to sorafenib]. Prog Urol; 2008 Jul;18(7):480-2
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Régression d'un thrombus cave néoplasique sous traitement par sorafénib.
  • Ten percent of patients with kidney cancer have associated vena cava thrombus, which is associated with a high operative morbidity.
  • Up to now, no medical treatment has allowed regression of vena cava tumour thrombus.
  • The authors report the case of a 62-year-old patient with left kidney cancer associated with vena cava tumour thrombus.
  • After surgical resection, the patient relapsed in the form of vena cava thrombus associated with right renal vein thrombus, responsible for renal insufficiency requiring dialysis.
  • Sorafenib therapy allowed regression of the vena cava thrombus, suspension of haemodialysis and local disease control with a follow-up of one year.
  • This case report justifies a review of the place of anti-angiogenic therapy in the treatment of kidney cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / complications. Kidney Neoplasms / complications. Protein Kinase Inhibitors / therapeutic use. Pyridines / therapeutic use. Renal Veins. Venae Cavae. Venous Thrombosis / drug therapy
  • [MeSH-minor] Follow-Up Studies. Humans. Kidney / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Nephrectomy. Niacinamide / analogs & derivatives. Phenylurea Compounds. Receptors, Vascular Endothelial Growth Factor. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602611.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


30. Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E: Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology; 2007;73(3-4):204-9
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
  • BACKGROUND: The aim of our study was to evaluate the efficacy and safety in unresectable or advanced renal carcinoma treated with sorafenib, in a situation closely similar to the everyday medical practice.
  • They were either previously untreated or relapsed after one or more previous treatments with systemic therapy.
  • Most of them had clear cell renal carcinoma (RCC), but other histological types such as papillary, chromophobe, Bellini ducts, sarcomatoid and mixed forms were also represented.
  • Response was observed in the majority of patients with RCC, but also in some patients with non-clear cell RCC.
  • CONCLUSIONS: The results confirm previous ones reported in the literature concerning the efficacy and the safety of sorafenib as second-line treatment in patients with RCC.
  • In addition, they disclose the hypothesis that sorafenib could be effective also in patients who underwent multiple previous treatments and in those with histology different from clear cells.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Pyridines / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / secondary. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Prognosis. Remission Induction. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18418013.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


31. Singhal S, Mehta J: Thalidomide in cancer. Biomed Pharmacother; 2002 Feb;56(1):4-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide in cancer.
  • Thalidomide has immunomodulatory and anti-angiogenic properties which may underlie its activity in cancer.
  • After its success in myeloma, it has been investigated in other plasma cell dyscrasias, myelodysplastic syndromes, gliomas, Kaposi's sarcoma, renal cell carcinoma, advanced breast cancer, and colon cancer.
  • Thalidomide causes responses in 30-50% of myeloma patients as a single agent, and acts synergistically with corticosteroids and chemotherapy.
  • Responses have also been seen in one-third of patients with Kaposi's sarcoma, in a small proportion of patients with renal cell carcinoma and high-grade glioma, and in some patients with colon cancer in combination with irinotecan.
  • The drug is being investigated currently in a number of clinical trials for cancer.
  • Thrombotic phenomena are especially common when thalidomide is combined with chemotherapy.
  • Adverse effects severe enough to necessitate cessation of therapy are seen in around 20% of patients.
  • A therapeutic trial of thalidomide is essential in all patients with relapsed or refractory myeloma.
  • In other cancers, the best way to use the drug is in the setting of clinical trials.
  • In the absence of access to studies or alternative therapeutic options, thalidomide could be considered singly or in combination with standard therapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Neoplasms / drug therapy. Thalidomide / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11905508.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Interleukin-2; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 61
  •  go-up   go-down


32. McDermott DF, George DJ: Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. Cancer Treat Rev; 2010 May;36(3):216-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data.
  • The availability of molecularly targeted agents has improved outcomes for patients with renal cell carcinoma (RCC), a disease long considered refractory to systemic therapy.
  • Bevacizumab, a potent and specific anti-VEGF monoclonal antibody, has demonstrated significant clinical benefits when used in combination with interferon-alfa (IFN-alpha) for the treatment of metastatic RCC in two randomized phase III trials.
  • The use of bevacizumab with IFN-alpha received approval in Europe for the first-line treatment of patients with advanced or metastatic RCC, and more recently this combination was approved for use in patients with mRCC in the United States.
  • Bevacizumab with IFN-alpha has also been recommended by the National Comprehensive Cancer Network for first-line therapy of relapsed or metastatic unresectable RCC with predominantly clear cell histology.
  • Collectively, these studies allow the role of bevacizumab-based therapy to be defined in the context of a new and evolving algorithm for the treatment of patients with advanced RCC.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20116176.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Number-of-references] 61
  •  go-up   go-down


33. Komeya M, Matsumoto T, Fujinami K, Senga Y, Asakura T, Goto A: [A case of recurrent intracaval renal cell carcinoma effectively treated with sunitinib]. Hinyokika Kiyo; 2010 Sep;56(9):499-503
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent intracaval renal cell carcinoma effectively treated with sunitinib].
  • A 67-year-old man received left radical nephrectomy for left renal cell carcinoma (RCC) (clear cell carcinoma, G2, pT3bN0M0).
  • A computed tomographic (CT) scan and magnetic resonance imaging reveal recurrent renal cell carcinoma in the inferior vena cava (IVC) and the left renal fossa, thrombus in the left external vein and acute pulmonary embolism.
  • We performed treatment with sunitinib for 5 months after anticoagulant therapy for 3 weeks.
  • A new CT scan showed disappearance of RCC in the IVC and reduction in the size of RCC in the renal fossa.
  • Only 11 cases are reported as recurrent RCC in the IVC.
  • We report the first case of recurrent intracaval RCC in which sunitinib treatment was effective.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / pathology. Indoles / therapeutic use. Kidney Neoplasms / pathology. Pyrroles / therapeutic use. Vascular Neoplasms / drug therapy. Vena Cava, Inferior

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20940524.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


34. Richardson P, Hideshima T, Anderson K: Thalidomide: emerging role in cancer medicine. Annu Rev Med; 2002;53:629-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide: emerging role in cancer medicine.
  • Food and Drug Administration in 1998, and more recently certain malignancies, including multiple myeloma.
  • Moreover, clinical trials have confirmed benefit in relapsed disease, and the role of thalidomide in treating newly diagnosed patients is currently under study.
  • Its use in other tumors is under evaluation, with promise in renal cell carcinoma, prostate cancer, glioma, and Kaposi's sarcoma.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Angiogenesis Inhibitors / therapeutic use. Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Animals. Clinical Trials as Topic. Humans. Multiple Myeloma / drug therapy. Palliative Care. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11818493.001).
  • [ISSN] 0066-4219
  • [Journal-full-title] Annual review of medicine
  • [ISO-abbreviation] Annu. Rev. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Angiogenesis Inhibitors; 0 / Tumor Necrosis Factor-alpha; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 111
  •  go-up   go-down


35. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG: Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol; 2008 Jul;180(1):94-8
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
  • PURPOSE: Targeted molecular therapies such as bevacizumab, sunitinib and sorafenib before surgical resection hold promise as rational treatment paradigms for patients with metastatic or locally recurrent renal cell carcinoma.
  • To analyze the safety of this approach we evaluated surgical parameters and perioperative complications in patients treated with targeted molecular therapies before cytoreductive nephrectomy or resection of retroperitoneal renal cell carcinoma recurrence, and compared them to a matched patient cohort who underwent up-front surgical resection.
  • MATERIALS AND METHODS: We evaluated surgical parameters and perioperative complications in 44 patients treated with targeted molecular therapies before cytoreductive nephrectomy or resection of local renal cell carcinoma recurrence, and in a matched cohort of 58 patients who underwent up-front surgery.
  • RESULTS: Cohorts of patients treated with preoperative targeted molecular therapy and initial surgical resection were matched in terms of clinical characteristics, burden of metastatic disease and number of adverse prognostic factors.
  • A total of 39 complications occurred in 17 (39%) patients treated with preoperative targeted molecular therapy and in 16 (28%) who underwent up-front resection (p = 0.287).
  • There were no statistically significant differences in surgical parameters, incidence of perioperative mortality, re-exploration, readmission, thromboembolic, cardiovascular, pulmonary, gastrointestinal, infectious or incision related complications between patients treated with preoperative targeted molecular therapy and those who underwent up-front surgery.
  • Duration, type and interval from targeted molecular therapy to surgical intervention were not associated with the risk of perioperative morbidity.
  • CONCLUSIONS: Preoperative administration of targeted molecular therapies is safe, and does not increase surgical morbidity or perioperative complications in patients treated with cytoreductive nephrectomy or resection of recurrent retroperitoneal renal cell carcinoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / surgery. Indoles / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Nephrectomy. Postoperative Complications / epidemiology. Postoperative Complications / etiology. Pyridines / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Preoperative Care

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2009 Apr;55(4):990-1 [19650236.001]
  • (PMID = 18485389.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


36. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J: Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer; 2008 Jul;61(1):82-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
  • BACKGROUND: Preclinical pharmacological properties of mapatumumab (agonistic human monoclonal antibody to TRAIL-R1) suggest that this antibody reduces cell viability, induces cell death in many types of cancer cell lines in vitro, inhibits or reduces tumor growth in xenograft models of solid tumors, and can induce significant tumor regression in some models.
  • The receptor for mapatumumab, TRAIL-R1, is expressed on NSCLC cell lines.
  • This pharmacologic profile suggests that mapatumumab may have therapeutic benefit in the treatment of NSCLC.
  • METHODS: This Phase 2 multi-center study was designed to evaluate the efficacy, safety, and tolerability of mapatumumab in patients with advanced non-small cell lung cancer (NSCLC) previously treated with at least 1 platinum-based regimen.
  • RESULTS: A total of 32 patients with relapsed or refractory Stage IIIB or IV or recurrent NSCLC were enrolled.
  • Patients had received a median of 3 previous therapeutic regimens (range 1-7).
  • Laboratory analyses revealed no appreciable evidence of hepatic or renal toxicity among the study patients.
  • No patients developed anti-mapatumumab antibodies.
  • CONCLUSION: In a group of heavily pretreated NSCLC patients, no objective single agent activity of mapatumumab was demonstrated, but the drug was safe and well tolerated.
  • Based on this favorable safety profile, and preclinical evidence of potential synergy in combination with agents commonly used to treat NSCLC, future evaluation of mapatumumab in combination with chemotherapy is warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Receptors, Tumor Necrosis Factor / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18255187.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF10A protein, human; 0 / mapatumumab
  •  go-up   go-down


37. Wertel I, Barczynski B, Kotarski J: The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment. Front Biosci; 2008;13:2177-90
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of dendritic cells in cytotoxic immune response regulation in ovarian cancer micro-environment.
  • Ovarian cancer is the most lethal gynecological malignancy.
  • At the time of diagnosis most patients present with an advanced stage of the disease and require multidisciplinary systemic treatment, including surgery and adjuvant chemotherapy.
  • Despite good initial response to cytostatics, the vast majority of patients develops a recurrence and will need novel therapeutic strategies, as relapsed ovarian cancer is still incurable.
  • One promising treatment option is the use of dendritic cells (DCs) which might induce effective anti-tumor immunity.
  • The ability of DCs to generate an anti-cancer response has been documented in various kinds of human tumors, including malignant melanoma, renal cell carcinoma, and breast cancer tumors.
  • Although DCs were identified in the micro-environment of ovarian cancer, lack of clearly defined ovarian-specific tumor antigens capable of being recognized by T cells is considered the major prohibiting factor in ovarian cancer vaccine development.
  • In this review we will focus on current knowledge of the influence of DC mechanisms of cytotoxic T-cell responses and recent advances in DC identification in ovarian cancer patients, in addition to summarizing the data on DC vaccinations in these patients.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981701.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Ligands
  • [Number-of-references] 142
  •  go-up   go-down


38. Reinhard H, Aliani S, Ruebe C, Stöckle M, Leuschner I, Graf N: Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study. J Clin Oncol; 2004 Nov 15;22(22):4500-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor stages were defined according to SIOP, and treatment was risk-adapted according to SIOP 93-01/Society for Pediatric Oncology and Hematology (GPOH) protocol.
  • RESULTS: Ten patients (33%) had metastatic disease at the time of diagnosis (liver, four patients; lung, three patients; liver and lung, three patients).
  • Histologic studies revealed intermediate-risk in 23 of 30 tumors; two tumors were classified as high-risk; and three tumors were clear-cell sarcomas.
  • Two of 30 patients showed a nephroblastoma and a renal cell carcinoma simultaneously in the same kidney.
  • A complete remission was achieved in 24 patients; four patients relapsed after complete remission; and three of them reached a second remission with further treatment.
  • Event-free survival was 57%, with an overall survival of 83% (median observation time, 4 years).
  • CONCLUSION: Adults can be cured in a high percentage by a multimodal treatment according to pediatric protocols.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Wilms Tumor / drug therapy. Wilms Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542800.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Mismatched double-stranded RNA: polyI:polyC12U. Drugs R D; 2004;5(5):297-304
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ampligen, currently under development by Hemispherx Biopharma in the US, acts on the immunological system through T-lymphocyte stimulation and is indicated for the treatment of chronic fatigue syndrome and acquired immunodeficiency deficiency syndrome (AIDS), as part of the combined therapy.
  • In February 2004, Fujisawa Deutschland GmbH, a subsidiary of Fujisawa Pharmaceutical Co., entered into an option agreement with Hemispherx Biopharma with the intent of becoming a distributor for Ampligen for the potential treatment of chronic fatigue syndrome in Germany, Switzerland and Austria.
  • The agreement stipulates that the Guangdong Medicine Group Corporation (GMC) will conduct clinical trials with Ampligen for the treatment of HIV.
  • In May 2003, Hemispherx Biopharma and the Center for Cell and Gene Therapy entered into a research project agreement that will see Ampligen implemented in a protocol used in patients with relapsed EBV-positive Hodgkin's Lymphoma.
  • In March 2002, Esteve and Hemispherx Biopharma entered into a collaborative agreement under which Esteve will be the sole distributor of Ampligen in Spain, Portugal and Andorra for the treatment of chronic fatigue syndrome.
  • Under this agreement, in addition to other terms, Esteve will also collaborate in the drug product development by conducting clinical studies in Spain in patients coinfected with HIV/HCV.
  • In July 2001 Hemispherx Biopharma announced that it had formed a strategic alliance with Empire Health Resources for clinical trials of Ampligen in the treatment of HIV and hepatitis C virus infections.
  • Hemispherx and AOP Orphan Pharmaceuticals have signed a marketing agreement for Ampligen for the treatment of chronic fatigue syndrome for Austria, the Czech Republic, Poland and Hungary.
  • In the US, Ampligen has been granted orphan drug status for the treatment of AIDS, renal cell carcinoma (phase II, completed), chronic fatigue syndrome (phase III) and invasive/metastatic malignant melanoma (phase II).
  • Previously, Hemispherx submitted an application to the EMEA for the approval of Ampligen for the treatment of chronic fatigue syndrome; the first stage of th;) for the treatment of chronic fatigue syndrome; the first stage of the regulatory review has been cleared.
  • In 2000, Hemispherx Europe (Hemispherx) obtained orphan drug status for Ampligen for the treatment of chronic fatigue syndrome in the EU, providing Hemispherx with 10 years of marketing exclusivity following the launch of the drug, as well as potential financial research benefits for the agent.
  • In February 2000, Crystaal Corporation (now Biovail Pharmaceuticals Canada) acquired exclusive marketing rights to Ampligen in Canada, where it submitted an NDA for the agent for the treatment of chronic fatigue syndrome.
  • In the meantime, Ampligen has been available since May 1996 under the Canadian Emergency Drug Release Programme for the treatment of chronic fatigue syndrome and immune dysfunction syndrome by Rivex Pharma (Helix BioPharma).
  • Bioclones has initiated clinical studies with Ampligen for the treatment of chronic fatigue syndrome in Australia.
  • Clinical treatment programmes for chronic fatigue syndrome in other Pacific Rim countries are planned.
  • Hemispherx has developed a 'ready-to-use' liquid formulation of the drug and has begun treating patients with chronic fatigue syndrome in ongoing clinical trials.
  • Hemispherx has also developed an oral version of the drug (Oragen), which is undergoing preclinical evaluation.
  • In February 2001, Hemispherx Biopharma announced that it was initiating phase II/III trials of Ampligen in the treatment of late-stage, multidrug-resistant strains of HIV in the European Union.
  • Patients treated in these studies will have exhausted all other treatment options.
  • The trial, comprising two studies, REARMI and REARMII (Research/Evaluation of Ampligen for Retroviral Mutations I and II), will evaluate the ability of Ampligen to prevent the emergence of mutated, drug-resistant strains of the virus.
  • 'Several hundred' patients currently on antiretroviral therapy and at risk of viral relapse will be enrolled at centres in Connecticut, New York, Florida and California.
  • A second phase IIb study evaluating the effect of Ampligen on structured treatment interruptions (STI) is also underway.
  • NIH sponsored studies of potential therapies for SARS have identified Ampligen as having unusually high and consistent antiviral activity against human coronavirus, the pathogen implicated as the causative agent of the disease.
  • In May 2004 Hemispherx announced that it had filed an expanded US patent application covering the use of Ampligen for the potential treatment and prevention of severe acute respiratory syndrome (SARS) and dreaded emerging viruses.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Poly I-C / therapeutic use. Poly U / therapeutic use. RNA, Double-Stranded / therapeutic use. Virus Diseases / drug therapy
  • [MeSH-minor] Animals. Anti-HIV Agents / pharmacology. Anti-HIV Agents / therapeutic use. Base Pair Mismatch. Drug Interactions. Hepatitis B / drug therapy. Humans. Mice. Nervous System Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Adis Data Information BV
  • (PMID = 15357629.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / RNA, Double-Stranded; 0 / poly(I).poly(c12,U); 24939-03-5 / Poly I-C; 27416-86-0 / Poly U
  •  go-up   go-down


40. Tarhini A, Kotsakis A, Gooding W, Shuai Y, Petro D, Friedland D, Belani CP, Dacic S, Argiris A: Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res; 2010 Dec 1;16(23):5900-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.
  • PURPOSE: Mammalian target of rapamycin (mTOR) is a promising target in small cell lung cancer (SCLC).
  • We designed a phase II study of everolimus, an mTOR inhibitor, in previously treated, relapsed SCLC.
  • PI3K/Akt signaling pathway biomarkers were evaluated on baseline tumor tissue.
  • Median survival was 6.7 months and median time to progression was 1.3 months.
  • Grade 3 toxicities included thrombocytopenia (n = 2), neutropenia (n = 2), infection (n = 2), pneumonitis (n = 1), fatigue (n = 1), elevated transaminases (n = 1), diarrhea (n = 2), and acute renal failure (n = 1).
  • CONCLUSIONS: Everolimus was well tolerated but had limited single-agent antitumor activity in unselected previously treated patients with relapsed SCLC.
  • [MeSH-major] Lung Neoplasms / drug therapy. Sirolimus / analogs & derivatives. Small Cell Lung Carcinoma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease Progression. Everolimus. Female. Humans. Male. Middle Aged. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 21045083.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


41. Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, Luo FR, Wojtowicz-Praga S, Percent I, Saleh M: Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm; 2010 Feb;25(1):13-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A phase I trial of tigatuzumab in patients with relapsed/refractory carcinomas (n = 16) or lymphoma (n = 1) was designed to determine the maximal tolerated dose (MTD), pharmacokinetics, immunogenicity, and safety.
  • There were no study-drug-related grade 3 or 4, renal, hepatic, or hematologic toxicities.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 1995 Dec;3(6):673-82 [8777713.001]
  • [Cites] J Immunol. 1994 Jun 15;152(12):5624-32 [7515909.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9394-407 [16361639.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2390-3 [16638843.001]
  • [Cites] Future Oncol. 2006 Aug;2(4):493-508 [16922616.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1390-5 [17416859.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2313-7 [17438088.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):291-8 [17303227.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5535s-5543s [17875786.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6187-94 [17947486.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3198-207 [18089714.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):591-7 [18177927.001]
  • [Cites] Cell Mol Immunol. 2008 Feb;5(1):55-60 [18318995.001]
  • [Cites] Cell Death Differ. 2008 Apr;15(4):751-61 [18219321.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2180-9 [18381960.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):507-16 [18474311.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer Immunol Immunother. 2004 Mar;53(3):153-9 [14749900.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3731-41 [14506165.001]
  • [Cites] Nat Med. 2001 Aug;7(8):954-60 [11479629.001]
  • [Cites] Gene Ther. 2004 Apr;11(8):658-67 [14973547.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Immunity. 1997 Dec;7(6):821-30 [9430227.001]
  • (PMID = 20187792.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R21 CA115013-02
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 918127-53-4 / tigatuzumab
  • [Other-IDs] NLM/ PMC2883819
  •  go-up   go-down






Advertisement